EP Patent

EP2167489A2 — Pyrimidine derivatives useful as raf kinase inhibitors

Assigned to Millennium Pharmaceuticals Inc · Expires 2010-03-31 · 16y expired

What this patent protects

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

USPTO Abstract

The present invention provides compounds useful as inhibitors of Raf protein kinase. The present invention also provides compositions thereof, and methods of treating Raf-mediated diseases.

Drugs covered by this patent

Ojemda (TOVORAFENIB) · Day One Biopharms

Patent Metadata

Patent number: EP2167489A2
Jurisdiction: EP
Classification: —
Expires: 2010-03-31
Drug substance claim: No
Drug product claim: No
Assignee: Millennium Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.